Stryker (NYSE:SYK) Upgraded by UBS Group to “Strong-Buy” Rating

Stryker (NYSE:SYK) was upgraded by UBS Group to a “strong-buy” rating in a research report issued to clients and investors on Tuesday,Zacks.com reports.

Several other research firms have also recently commented on SYK. Needham & Company LLC decreased their target price on shares of Stryker from $454.00 to $418.00 and set a “buy” rating for the company in a research report on Friday, May 1st. The Goldman Sachs Group reiterated a “neutral” rating and set a $361.00 price objective on shares of Stryker in a research report on Friday, May 1st. Leerink Partners lowered their target price on Stryker from $410.00 to $407.00 and set an “outperform” rating on the stock in a research report on Friday, June 5th. BTIG Research set a $371.00 target price on Stryker in a research note on Monday, July 13th. Finally, Canaccord Genuity Group decreased their price target on Stryker from $435.00 to $400.00 and set a “buy” rating for the company in a research note on Friday, May 1st. Two research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $393.39.

Stryker Price Performance

Shares of NYSE SYK opened at $346.59 on Tuesday. Stryker has a 1-year low of $281.00 and a 1-year high of $403.92. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.11 and a quick ratio of 1.25. The business’s fifty day moving average price is $315.76 and its two-hundred day moving average price is $335.22. The firm has a market capitalization of $132.87 billion, a PE ratio of 40.11, a P/E/G ratio of 2.16 and a beta of 0.77.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.98 by ($0.38). Stryker had a net margin of 13.20% and a return on equity of 23.42%. The firm had revenue of $6.02 billion for the quarter, compared to analyst estimates of $6.34 billion. During the same period last year, the firm posted $2.84 EPS. The business’s revenue was up 2.6% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. On average, research analysts expect that Stryker will post 14.99 EPS for the current year.

Insider Transactions at Stryker

In other news, VP Robert S. Fletcher sold 4,544 shares of the company’s stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total value of $1,394,417.28. Following the completion of the sale, the vice president owned 10,582 shares in the company, valued at $3,247,298.34. This represents a 30.04% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of the firm’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total value of $96,791,300.00. Following the transaction, the director directly owned 1,924,880 shares of the company’s stock, valued at $601,005,282.40. This represents a 13.87% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 323,264 shares of company stock valued at $100,659,489. Corporate insiders own 4.60% of the company’s stock.

Institutional Trading of Stryker

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Sankala Group LLC acquired a new position in Stryker in the fourth quarter worth approximately $26,000. Godfrey Financial Associates Inc. purchased a new stake in shares of Stryker during the fourth quarter valued at $26,000. United Financial Planning Group LLC acquired a new position in shares of Stryker in the 3rd quarter valued at $27,000. Atlas Capital Advisors Inc. purchased a new position in Stryker in the 4th quarter worth about $27,000. Finally, DJE Kapital AG acquired a new stake in Stryker during the 4th quarter worth about $28,000. 77.09% of the stock is currently owned by institutional investors.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.